In a recent transaction, Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a pharmaceutical company, sold 525 shares of the company’s common stock at an average price of $15.00, totaling approximately $7,875. On the same day, Rodman also acquired 525 shares of Mineralys Therapeutics’ common stock at a price of $1.08 per share, amounting to a total of $567.
The sales were conducted in multiple transactions at prices ranging from $15.00 to $15.01, with the average price coming to $15.0011 per share. These transactions took place on July 16, 2024, and were reported to have been carried out under a prearranged 10b5-1 trading plan, which Rodman had adopted on November 14, 2023.
Following the sale, Rodman’s ownership in Mineralys Therapeutics’ common stock decreased to 102,873 shares. The transactions indicate Rodman’s continued investment in the company, as evidenced by his simultaneous acquisition of shares at a significantly lower price point.
The Form 4 filing also disclosed that Rodman exercised options to acquire the 525 shares of common stock. The exercise price for these stock options was noted at $1.08 per share, which had been previously misreported due to a rounding error. The options vested with 25% of the underlying shares on July 12, 2023, and will continue to vest in substantially equal monthly installments over the following 36 months, with an expiration date of July 11, 2032.
Investors and the public can request full details regarding the number of shares sold at each separate price within the range from the reporting person, as per the footnote in the SEC filing.
Mineralys Therapeutics specializes in pharmaceutical preparations and is incorporated in Delaware. The company’s common stock is traded on the NASDAQ under the ticker symbol MLYS. These recent transactions by a key executive are part of the ongoing financial disclosures required by the Securities and Exchange Commission.
In other recent news, Mineralys Therapeutics has been making significant strides in its clinical trials and corporate governance. The company has been advancing its lead oral candidate, lorundrostat, through Phase 3 pivotal development with the expectation of topline data from these trials in late 2024 and 2025. The treatment aims to address the needs of millions of Americans suffering from uncontrolled hypertension and chronic kidney disease. Analyst firm H.C. Wainwright has initiated coverage on Mineralys Therapeutics, setting a Buy rating based on the positive results from the Phase 2 Target-HTN trial.
In addition to the trials, Mineralys Therapeutics has seen changes in its board of directors. The company recently appointed Dr. Alexander M. Gold to its Board of Directors and the Nominating and Corporate Governance Committee. Dr. Gold brings extensive experience in clinical development from his tenure at various pharmaceutical firms. Concurrently, Dr. Olivier Litzka resigned from the Board, reducing its size to seven members.
The company also reported its Q1 2024 financial results, highlighting the potential of lorundrostat to significantly lower blood pressure in patients with uncontrolled or resistant hypertension. With robust funding of $338.6 million, Mineralys is advancing its clinical trials, with top-line data expected from its Advance-HTN trial in Q4 2024 and from the Launch-HTN trial in the second half of 2025. These developments highlight Mineralys Therapeutics’ ongoing efforts in the hypertension and kidney disease treatment landscape.
InvestingPro Insights
Amid the recent insider transactions at Mineralys Therapeutics, Inc. (NASDAQ:MLYS), investors may find it valuable to consider the company’s financial health and market performance. According to InvestingPro, MLYS holds more cash than debt on its balance sheet, which can be a positive sign of financial stability. Additionally, the company’s liquid assets exceed its short-term obligations, suggesting that it has a solid liquidity position to meet near-term liabilities.
On the market performance front, Mineralys Therapeutics has demonstrated strong returns, with a notable 26.7% price total return over the last three months and an impressive 64.69% over the last six months as of Q1 2024. Despite this positive momentum, the company does not pay a dividend to shareholders, which might be a consideration for income-focused investors.
The latest InvestingPro Data metrics provide further insight into the company’s valuation and profitability. As of Q1 2024, MLYS has a market capitalization of 689.62 million USD. However, the company’s P/E ratio stands at -5.87, reflecting that it is not currently profitable. Moreover, the P/E ratio adjusted for the last twelve months is even lower at -7.6, underscoring the company’s challenges in generating earnings. Additionally, the return on assets for the same period is -27.78%, which could raise concerns about asset efficiency.
For those interested in a deeper analysis, there are additional InvestingPro Tips available which highlight that analysts have revised their earnings estimates downwards for the upcoming period and do not anticipate the company to be profitable this year. Furthermore, MLYS suffers from weak gross profit margins and has not been profitable over the last twelve months. For a comprehensive understanding of Mineralys Therapeutics’ financial outlook and to access more exclusive insights, investors are encouraged to use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. There are 11 additional tips listed in InvestingPro that can provide investors with a more nuanced view of the company’s prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.